One limitation of the study is our inability to determine the prevalence of ERBB2 alterations by tumor type as some tumors where NGS testing has been commonplace for longer, such as NSCLC, are likely to be over-represented in our database [8]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.